NEW YORK, NY / ACCESSWIRE / August 23, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Kanzhun Limited (NASDAQ:BZ)
CONTACT JAKUBOWITZ ABOUT BZ:
https://claimyourloss.com/securities/kanzhun-limited-loss-submission-form/?id=18820&from=1
Class Period : June 11, 2021 - July 2, 2021
Lead Plaintiff Deadline : September 10, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Kanzhun would face an imminent cybersecurity review by the Cyberspace Administration of China ("CAC"); (2) the CAC would require Kanzhun to suspend new user registration on its BOSS Zhipin app; (3) Kanzhun needed to "to conduct a comprehensive examination of cybersecurity risks"; (4) Kanzhun needed to "enhance its cybersecurity awareness and technology capabilities"; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Iterum Therapeutics Plc (NASDAQ:ITRM)
CONTACT JAKUBOWITZ ABOUT ITRM:
https://claimyourloss.com/securities/iterum-therapeutics-plc-loss-submission-form/?id=18820&from=1
Class Period : November 30, 2020 - July 23, 2021
Lead Plaintiff Deadline : October 4, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Selectquote, Inc. (NYSE:SLQT)
CONTACT JAKUBOWITZ ABOUT SLQT:
https://claimyourloss.com/securities/selectquote-inc-loss-submission-form/?id=18820&from=1
Class Period : February 8, 2021 - May 11, 2021
Lead Plaintiff Deadline : October 15, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/660877/LAWSUITS-FILED-AGAINST-BZ-ITRM-and-SLQT--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS
